Everything below concerns mass spectrometry. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
== Nuclear energy applications == In a fission nuclear reactor, uranium-238 can be used to generate plutonium-239, which itself can be used in a nuclear weapon or as a nuclear-reactor fuel supply. In a typical nuclear reactor, up to one-third of the generated power comes from the fission of 239Pu, which is not supplied as a fuel to the reactor, but rather, produced from 238U. A certain amount of production of 239Pu from 238U is unavoidable wherever it is exposed to neutron radiation. Depending on burnup and neutron temperature, different shares of the 239Pu are converted to 240Pu, which determines the "grade" of produced plutonium, ranging from weapons grade, through reactor grade, to plutonium so high in 240Pu that it cannot be used in current reactors operating with a thermal neutron spectrum. The latter usually involves used "recycled" MOX fuel which entered the reactor containing significant amounts of plutonium.
== Clinical significance == Furin is one of the proteases responsible for the proteolytic cleavage of HIV envelope polyprotein precursor gp160 to gp120 and gp41 prior to viral assembly. This protease is also thought to play a role in tumor progression. The use of alternate polyadenylation sites has been found for the FURIN gene. Furin is enriched in the Golgi apparatus, where it functions to cleave other proteins into their mature/active forms. Furin cleaves proteins just downstream of a basic amino acid target sequence (canonically, Arg-X-(Arg/Lys) -Arg'). In addition to processing cellular precursor proteins, furin is also used by a number of pathogens. For example, the envelope proteins of viruses such as HIV, influenza, dengue fever, several filoviruses including ebola and marburg virus, and the spike protein of SARS-CoV-2, must be cleaved by furin or furin-like proteases to become fully functional. When SARS-CoV-2 virus is being synthesized in an infected cell, furin or furin-like proteases cleave the spike protein into two portions (S1 and S2), which remain associated. Anthrax toxin, Pseudomonas exotoxin, and papillomaviruses must be processed by furin during their initial entry into host cells. Inhibitors of furin are under consideration as therapeutic agents for treating anthrax infection. Furin is regulated by cholesterol and substrate presentation. When cholesterol is high, furin traffics to GM1 lipid rafts. When cholesterol is low, furin traffics to the disordered region. This is speculated to contribute to cholesterol and age dependent priming of SARS-CoV.
Administration: Administers the Secretariat as well as looks after personal matters of the Chairman/Members and other Officers/Staff of the commission. All India Services: Recruitment to All India Services is done either by direct recruitment, through Civil Services Examination or by promotion from the State Service. The AIS Branch handles the promotions of State Service officers to the IAS, IPS and IFS. It also handles policy matters relating to All India Services and amendments in the 'Promotion Regulations' of respective services. Appointments: It carries out appointments to central services based on Promotion (based on proposals from various Ministries/Departments/Union Territories and from certain local bodies) and by the means of Deputation and Absorption. Examinations: It carries out merit-based selection and recommendation of candidates through various examinations such as the Engineering Services Examination, Combined Medical Services Examination, Defence Services Examination, Civil Services Examination, etc., to Group A and Group B Services of the Government of India. General: Primarily deals with day-to-day housekeeping work for the Commission, such as arrangements and facilitation for the conduct of Examinations by the UPSC, printing the Annual Report, etc.
Sources: en.wikipedia.org
=== Psychosocial === Psychosocial interventions are used as an adjunct to pharmaceutical treatment and can be classified within behavior-, emotion-, cognition- or stimulation-oriented approaches. Behavioral interventions attempt to identify and reduce the antecedents and consequences of problem behaviors. This approach has not reported success in improving overall functioning, but can help to reduce some specific problem behaviors, such as incontinence. There is a lack of high quality data on the effectiveness of these techniques in other behavior problems such as wandering. Music therapy is effective in reducing behavioral and psychological symptoms. Emotion-oriented interventions include reminiscence therapy, validation therapy, supportive psychotherapy, sensory integration, also called snoezelen, and simulated presence therapy. A Cochrane review has found no evidence that this is effective. Reminiscence therapy (RT) involves the discussion of past experiences, individually or in groups, many times with the aid of photographs, household items, music and sound recordings, or other familiar items from the past. A 2018 review of the effectiveness of RT found that effects were inconsistent, small in size, and of doubtful clinical significance, and varied by setting. Simulated presence therapy (SPT) is based on attachment theories and involves playing a recording with the voices of the closest relatives of the person with AD. There is partial evidence indicating that SPT may reduce challenging behaviors.
== Reaction == The journalist David Miller, writing for The Times, described Cambridge's victory as "crushingly conclusive". Cambridge's Malcolm Baker said: "We knew we could do it after about 25 strokes." Behrens explained "Our strength was that we were more uniform than Oxford. We have proved that you do not have to be an Olympic champion to win the Boat Race." The Oxford Boat Club president Pinsent conceded: "They put right a lot of mistakes they have made in the past, and they rowed outstandingly well." Spracklen agreed: "Cambridge got too far away. They were a better boat in that race. All credit to them." Cambridge's number two, David Gillard, said "there was a lot of revenge out there". Writing in The Independent, the journalist Chris Arnot noted that the Cambridge crew had used creatine supplements in order to attempt to enhance their performance. Used extensively at the 1992 Olympics, by athletes including Linford Christie and Sally Gunnell, and given to horses and greyhounds, creatine was believed to provide legal energy-enhancing effects to the crew.
Microglial cells: Microglia are macrophage cells that make up the primary immune system for the CNS. They are the smallest neuroglial cell. Astrocytes: Star-shaped macroglial cells with many processes found in the CNS. They are the most abundant cell type in the brain, and are intrinsic to a healthy CNS. Oligodendrocytes: CNS cells with very few processes. They form myelin sheaths on the axons of a neuron, which are lipid-based insulation that increases the speed at which the action potential, can travel down the axon. NG2 glia: CNS cells that are distinct from astrocytes, oligodendrocytes, and microglia. They serve as the developmental precursors of oligodendrocytes. Schwann cells: The PNS equivalent of oligodendrocytes, they help maintain axons and form myelin sheaths in the PNS. Satellite glial cell: Line the surface of neuron cell bodies in ganglia (groups of nerve body cells bundled or connected together in the PNS) Enteric glia: Found in the enteric nervous system, within the gastrointestinal tract.
Sources: en.wikipedia.org
Subclass † Endoceratoidea. Not used by Flower, e.g. Flower and Kummel 1950, interjocerids included in the Endocerida. Order † Endocerida Order † Intejocerida Subclass † Actinoceratoidea Not used by Flower, ibid Order † Actinocerida Subclass Nautiloidea Nautiloidea in the restricted sense. Order † Ellesmerocerida Plectronocerida subsequently split off as separate order. Order † Orthocerida Includes orthocerids and pseudorthocerids Order † Ascocerida Order † Oncocerida Order † Discosorida Order † Tarphycerida Order † Barrandeocerida A polyphyletic group included in the Tarphycerida Order Nautilida Subclass † Bactritoidea Order † Bactritida Paleozoic Ammonoidea (Miller, Furnish and Schindewolf, 1957)
== Large Scale Preparation == Dalfopristin is synthesized from pristinamycine IIa through achieving a stereoselective Michael-type addition of 2-diethylaminoethanethiol on the conjugated double bond of the dehydroproline ring . The first method found was using sodium periodate associated with ruthenium dioxide to directly oxidize the sulfur derivative into a sulfone. However, using hydrogen peroxide with sodium tungstate in a 2-phase medium produces an improved yield, and is therefore the method of choice for large scale production. The production of the dalfopristin portion of quinupristin/dalfopristin is achieved through purifying cocrystallization of the quinupristin and dalfopristin from acetone solutions.
=== CSIR India === In 2009, Ayyadurai was hired by India's Council of Scientific and Industrial Research (CSIR), India's largest science agency, by its director general, Samir K. Brahmachari. CSIR was mandated to create a new company, CSIR Tech, that would establish businesses using the research conducted by the country's many publicly owned laboratories. Ayyadurai reported that he had spent months trying to create a business plan for CSIR Tech, but received no response from Brahmachari. Ayyadurai then distributed a draft plan, which was not authorized by CSIR, to the agency's scientists that requested feedback and criticized management. His job offer was subsequently withdrawn five months after the position was offered. Brahmachari said that "the offer was withdrawn as [Ayyadurai] did not accept the terms and conditions and demanded unreasonable compensation." In its report, The New York Times said that "going public with such accusations is highly unusual. Mr. Ayyadurai circulated his paper not just to the agency's scientists but to journalists, and wrote about his situation to Prime Minister Manmohan Singh." In that letter, Ayyadurai said his report was intended to explore institutional barriers to CSIR's entrepreneurial mandate. He said that CSIR scientists reported that "they work in a medieval, feudal environment" that required a "major overhaul". The letter was co-authored by a colleague, Deepak Sardana.
CNMamide (CNMa) is a cyclic neuropeptide identified by computational analysis of Drosophila melanogaster protein sequences and named after its C-terminal ending motif. A gene encoding CNMa was found in most arthropods and comparison among the precursor sequences of several representative species revealed high conservation, particularly in the region of the predicted mature peptide. Two conserved cysteine residues enveloping four amino acids form a disulfide bond and were shown to be important for binding of the peptide to its receptor. Expression of CNMa was confirmed in the larval and adult brain of D. melanogaster but the function of the peptide has not been elucidated yet.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Purity is normally given as a percentage from reversed-phase HPLC, calculated as the main peak area relative to total peak area. Research-grade material is commonly specified at 95 per cent or higher, with tighter specifications available. The number is method-dependent and should be read alongside the chromatogram.